Herlev Hospital — Biomedical Watch V2

Traitements4programmes

Essais4liés

Publications8liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
SildenafilThis study is done to evaluate whether treatment with the drug sildenafil (Revatio®) can improve muscular, cardiac, cerebrovascular or cognitive function in patients with Beckers muscular dystrophy when compared to placebo (inactive medication). The study is based on the recent findings of an improved cardiac function in a mouse model of muscular dystrophy (Adamo et al 2010) and the previous findings of changed cognitive function in people with Becker dystrophy. In muscular dystrophy, the cellular protein, dystrophin is affected. During normal conditions, the enzyme neuronal nitric oxide synthase (nNOS), which produce nitric oxide (NO), is attached to dystrophin. NO is important in normal vascular function in each of muscle, heart and brain by stimulating production of cyclic GMP. However, in muscular dystrophy with dystrophin deficiency, nNOS do not have the normal cellular anchor, resulting in decreased NO levels and subsequent reduced cyclic GMP production. Sildenafil inhibits degradation of cGMP thus prolonging and increasing a cGMP response. Such effects are the basis for use of sildenafil in pulmonary hypertension and erectile dysfunction. Current hypothesis: Sildenafil restores the cyclic GMP function affected in muscular dystrophy wit nNOS deficiency resulting in improved muscle, cardiac, cerebrovascular and cognitive function.	Migraine, Myopathies	Phase 1	À vérifier	Denmark	À vérifier
SildenafilThis study is done to evaluate whether treatment with the drug sildenafil (Revatio®) can improve muscular, cardiac, cerebrovascular or cognitive function in patients with Beckers muscular dystrophy when compared to placebo (inactive medication). The study is based on the recent findings of an improved cardiac function in a mouse model of muscular dystrophy (Adamo et al 2010) and the previous findings of changed cognitive function in people with Becker dystrophy. In muscular dystrophy, the cellular protein, dystrophin is affected. During normal conditions, the enzyme neuronal nitric oxide synthase (nNOS), which produce nitric oxide (NO), is attached to dystrophin. NO is important in normal vascular function in each of muscle, heart and brain by stimulating production of cyclic GMP. However, in muscular dystrophy with dystrophin deficiency, nNOS do not have the normal cellular anchor, resulting in decreased NO levels and subsequent reduced cyclic GMP production. Sildenafil inhibits degradation of cGMP thus prolonging and increasing a cGMP response. Such effects are the basis for use of sildenafil in pulmonary hypertension and erectile dysfunction. Current hypothesis: Sildenafil restores the cyclic GMP function affected in muscular dystrophy wit nNOS deficiency resulting in improved muscle, cardiac, cerebrovascular and cognitive function.	Myopathies	Phase 2	À vérifier	Denmark	À vérifier
SildenafilThis study is done to evaluate whether treatment with the drug sildenafil (Revatio®) can improve muscular, cardiac, cerebrovascular or cognitive function in patients with Beckers muscular dystrophy when compared to placebo (inactive medication). The study is based on the recent findings of an improved cardiac function in a mouse model of muscular dystrophy (Adamo et al 2010) and the previous findings of changed cognitive function in people with Becker dystrophy. In muscular dystrophy, the cellular protein, dystrophin is affected. During normal conditions, the enzyme neuronal nitric oxide synthase (nNOS), which produce nitric oxide (NO), is attached to dystrophin. NO is important in normal vascular function in each of muscle, heart and brain by stimulating production of cyclic GMP. However, in muscular dystrophy with dystrophin deficiency, nNOS do not have the normal cellular anchor, resulting in decreased NO levels and subsequent reduced cyclic GMP production. Sildenafil inhibits degradation of cGMP thus prolonging and increasing a cGMP response. Such effects are the basis for use of sildenafil in pulmonary hypertension and erectile dysfunction. Current hypothesis: Sildenafil restores the cyclic GMP function affected in muscular dystrophy wit nNOS deficiency resulting in improved muscle, cardiac, cerebrovascular and cognitive function.	Migraine	Non applicable	À vérifier	Denmark	À vérifier
SildenafilThis study is done to evaluate whether treatment with the drug sildenafil (Revatio®) can improve muscular, cardiac, cerebrovascular or cognitive function in patients with Beckers muscular dystrophy when compared to placebo (inactive medication). The study is based on the recent findings of an improved cardiac function in a mouse model of muscular dystrophy (Adamo et al 2010) and the previous findings of changed cognitive function in people with Becker dystrophy. In muscular dystrophy, the cellular protein, dystrophin is affected. During normal conditions, the enzyme neuronal nitric oxide synthase (nNOS), which produce nitric oxide (NO), is attached to dystrophin. NO is important in normal vascular function in each of muscle, heart and brain by stimulating production of cyclic GMP. However, in muscular dystrophy with dystrophin deficiency, nNOS do not have the normal cellular anchor, resulting in decreased NO levels and subsequent reduced cyclic GMP production. Sildenafil inhibits degradation of cGMP thus prolonging and increasing a cGMP response. Such effects are the basis for use of sildenafil in pulmonary hypertension and erectile dysfunction. Current hypothesis: Sildenafil restores the cyclic GMP function affected in muscular dystrophy wit nNOS deficiency resulting in improved muscle, cardiac, cerebrovascular and cognitive function.	Migraine	Phase 1	À vérifier	Denmark	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Sildenafil	Migraine	Phase 1	NCT02795351	Induction of Migraine Aura With Sildenafil	COMPLETED
Sildenafil	Migraine	Non applicable	NCT05889455	COMPETE — Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab	COMPLETED
Cilostazol	Migraine	Phase 1	NCT02253004	Induction of Migraine Aura With Cilostazol	COMPLETED
Sildenafil	Myopathies	Phase 2	NCT01350154	Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients	COMPLETED

Publications

8

Molécule	Indication / population	Titre	Journal	Date
Sildenafil		Bridging fibrosis and function: an integrated mechanistic and therapeutic framework for Peyronie's disease and related erectile dysfunction.	Sexual medicine
Sildenafil		Narrative-based sexual medicine. A collection of patients' stories and clinical cases to better understand the management of erectile dysfunction with type 5 phosphodiesterase inhibitors in the real life.	The aging male : the official journal of the International Society for the Study of the Aging Male
Sildenafil		Sildenafil Positivity and Chronic Cardiac Pathology in Men Who Died of Ischemic Heart Disease: An Age- and Sex-Matched Postmortem Case-Control Study.	Diagnostics (Basel, Switzerland)
Sildenafil		Phosphodiesterase Type 5 Inhibitors as Chemical Hazards in Honey and Honey-Based Products.	Molecules (Basel, Switzerland)
Sildenafil		Selective pulmonary vasorelaxant effects of an N,N-diaminoquinazoline PDE5 inhibitor involving endothelial signaling and ion channel modulation.	European journal of pharmacology
Sildenafil		Sildenafil-associated severe cholestatic drug-induced liver injury presenting as persistent jaundice after stone extraction.	Clinical journal of gastroenterology
Sildenafil		Sildenafil for Attenuating Hepatic Ischemia-Reperfusion Injury and Promoting Liver Regeneration After Major (65%) Hepatectomy: A Porcine Pilot Study.	Cureus
Sildenafil		Bibliometric and Two-Sample Mendelian Randomization Analyses of the Causal Relationship Between Hypertension and Erectile Dysfunction.	Journal of visualized experiments : JoVE